Latest technology news and innovations
Federal health officials convene with major tech firms to discuss the future of clinical AI, aiming for safe implementation and regulatory clarity.
A clinical trial indicates potential for fecal microbiome transplants to improve peanut allergy tolerance, exciting experts in the field.
A child’s death in a CRISPR gene-editing trial by HuidaGene raises serious concerns about safety and regulatory oversight in China’s biotech sector.
Moderna has launched a clinical trial for its mRNA-based Ebola vaccine, marking a significant step in combating this viral disease.
Ramy Farid of Schrödinger reflects on the evolving role of AI in biotech, envisioning clearer perceptions in the industry within five years.
A recent Medicare pilot proposal risks reducing savings for retail drugs. Meanwhile, merger talks between AstraZeneca and Bristol Myers Squibb have been denied.
A new Medicaid toolkit emphasizes stricter oversight and measurable outcomes for autism therapies, raising concerns around ABA services and telehealth.
Excluding rare disease therapies from Medicare's drug pricing pilots could significantly reduce overall savings, according to recent research.
Despite high diagnosis rates, many U.S. men miss out on MRI screenings for prostate cancer, which could lead to better outcomes.
Novo Nordisk's ziltivekimab, aimed at targeting inflammation, showed no reduction in cardiovascular events despite lowering inflammation markers.
The American Diabetes Association, once praised for its bravery, now faces criticism for its handling of dissent within the medical community.
As advancements accelerate in rare disease therapies, LGMD patients face urgency, with time impacting their muscle function and access to new treatments.
In San Diego, a surge in syphilis cases highlights the challenges researchers face amid a drug shortage and complex patient interactions.
Capricor Therapeutics faces skepticism over its Duchenne MD therapy data, while the biotech sector grapples with leadership turmoil and FDA scrutiny.
Increased oil prices may significantly hike the cost of certain medicines, highlighting the need to reduce reliance on petrochemicals for production.
A recent FDA panel's critical vote against a Duchenne drug highlights ongoing scrutiny of digital health practices, particularly Hims & Hers.
Latigo Biotherapeutics' LTG-001 demonstrates significant pain relief in Phase 2 trials, marking a potential shift in non-opioid pain management options.
The FTC has initiated a lawsuit against Hims & Hers, accusing the telehealth firm of deceptive practices in consumer health data handling.
A fugitive assumed a new life in biotech, while a New Hampshire hospital challenges Eli Lilly's controversial pricing policies under the 340B program.
The debate over benchmarking clinical AI systems highlights the challenges of interpreting results beyond headlines.